Biologic Validation of Zr-89 Crefmirlimab Berdoxam CD8+ Minibody ImmunoPET in Human Brain Tumors
Latest Information Update: 06 Nov 2024
At a glance
- Drugs Crefmirlimab (Primary)
- Indications Brain cancer; Brain metastases; Glioma; Meningioma
- Focus Adverse reactions; Therapeutic Use
- 04 Nov 2024 Planned initiation date changed from 21 Oct 2024 to 30 Nov 2024.
- 24 Oct 2024 New trial record